Mirador Therapeutics closed a $250 million Series B to advance its precision immunology pipeline and signaled plans to consider an IPO later this year. The financing, led by major life‑science investors, will fund clinical development and build commercial readiness for Mirador’s lead programs. The company said the round supports scale‑up across discovery and translational studies. The raise underscores investor appetite for immunology platforms that promise precision targeting and faster path to proof‑of‑concept. For biotech financiers and strategists, Mirador’s fundraise and IPO talk highlight renewed public‑market receptivity for companies with clear near‑term clinical milestones.